Synthetic DNA manufacturer
DNA Script has raised €264M across 5 funding rounds from 24 investors, most recently a Series C round in Jan 2022. Based in Paris, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-01-05 | Series C | €31M | Baillie Gifford,eureKARE,Healthcor Management,Irving Investors,T. Rowe Price Associates | View deal → |
| 2021-10-29 | Series C | €142M | Farallon Capital,Agilent Technologies,Alexandria Venture Investments,Arrowmark Partners,Bpifrance Large Venture Fund,Casdin Capital+8 more | View deal → |
| 2020-07-29 | Series B | €46M | Casdin Capital | View deal → |
| 2019-04-01 | Series B | €34M | Bpifrance,Life Sciences Partners | View deal → |
| 2017-07-13 | Series A | €11M | Idinvest Partners,Illumina Ventures,Kurma Partners,Merck Ventures BV,Sofinnova Partners | View deal → |
